MOTS-c

MOTS-c is a 6.5–7.0/10 fit for people considering mitochondrial, metabolic health, blood sugar, energy, with the strongest case in the populations already represented by the evidence rather than broad wellness use. Lee 2015 and Kim 2018 give the report its main anchors. The benefits are context-dependent and the evidence still leaves responder, dose, and long-term questions open. MOTS-c makes the most sense when the target is concrete, such as a lab marker, symptom pattern, training limitation, or recovery bottleneck. It makes less sense as a background habit taken on faith. In practice, treat MOTS-c as a tracked experiment: define the outcome first, watch for tradeoffs, and let the response decide whether it earns a place.

✅ Best for: Metabolically unhealthy, sedentary, or aging adults who accept a research-peptide risk profile and want to test an exercise-mimetic AMPK signal while tracking objective biomarkers. MOTS-c is most relevant when fasting glucose, insulin resistance, body composition, fatigue, or low exercise capacity are the target, and especially when the user already has sleep, protein, resistance training, and low-intensity cardio basics in place. MOTS-c also fits advanced mitochondrial protocols where SS-31 comes first and MOTS-c follows as a signaling layer.

❌ Avoid if: You require human clinical-trial evidence before using an intervention, compete in tested sport, are pregnant or lactating, have active cancer involving mitochondrial or metabolic vulnerability, use glucose-lowering medication without clinician oversight, or cannot verify peptide source quality. MOTS-c is also a poor fit if you are healthy, trained, and insulin-sensitive, because exercise already induces endogenous MOTS-c signaling. Avoid MOTS-c if injection sterility, refrigeration, reconstitution, and sharps disposal feel like too much friction. Sourcing & dosing caveat: gray-market supply; score assumes clean, correctly-dosed material.